Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4

H. D. Preisler, Biaoru Li, J. Yang, R. W. Huang, E. Devemy, P. Venugopal, M. Tao, H. Chopra, S. A. Gregory, S. Adler, S. Sivaraman, P. Toofanfard, A. Jajeh, A. Galvez, E. Robin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

High levels of telomerase activity and high rates of cell proliferation are associated with a poor prognosis in acute myelogenous leukemia. Furthermore, cytokine production by leukemia cells is believed to play an important role in determining the proliferative characteristics of leukemia. The in vivo effects of two noncytotoxic agents on these parameters were determined in 33 acute myelogenous leukemia patients. Three daily doses of interleukin (IL) 4 or a single dose of amifostine reduced telomerase activity in the leukemia marrow cells in 7 of 9 and 11 of 13 patients, respectively. The administration of a single dose of amifostine resulted in a reduction in tumor necrosis factor α and IL-6 transcript levels in the marrow cells of 10 of 13 and 12 of 13 patients in which these transcripts were present. The administration of only three doses of IL-4 or a single dose of amifostine has a significant effect on leukemia cell parameters, which are believed to have a significant impact on the in vivo biology of the disease and on its response to remission induction therapy.

Original languageEnglish (US)
Pages (from-to)807-812
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number3
StatePublished - Mar 1 2000
Externally publishedYes

Fingerprint

Amifostine
Telomerase
Acute Myeloid Leukemia
Interleukin-4
Leukemia
Cytokines
Messenger RNA
Bone Marrow
Remission Induction
Interleukin-6
Tumor Necrosis Factor-alpha
Cell Proliferation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4. / Preisler, H. D.; Li, Biaoru; Yang, J.; Huang, R. W.; Devemy, E.; Venugopal, P.; Tao, M.; Chopra, H.; Gregory, S. A.; Adler, S.; Sivaraman, S.; Toofanfard, P.; Jajeh, A.; Galvez, A.; Robin, E.

In: Clinical Cancer Research, Vol. 6, No. 3, 01.03.2000, p. 807-812.

Research output: Contribution to journalArticle

Preisler, HD, Li, B, Yang, J, Huang, RW, Devemy, E, Venugopal, P, Tao, M, Chopra, H, Gregory, SA, Adler, S, Sivaraman, S, Toofanfard, P, Jajeh, A, Galvez, A & Robin, E 2000, 'Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4', Clinical Cancer Research, vol. 6, no. 3, pp. 807-812.
Preisler, H. D. ; Li, Biaoru ; Yang, J. ; Huang, R. W. ; Devemy, E. ; Venugopal, P. ; Tao, M. ; Chopra, H. ; Gregory, S. A. ; Adler, S. ; Sivaraman, S. ; Toofanfard, P. ; Jajeh, A. ; Galvez, A. ; Robin, E. / Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 3. pp. 807-812.
@article{3f8d3cfa49c147a1b3fb2462e86c9bee,
title = "Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4",
abstract = "High levels of telomerase activity and high rates of cell proliferation are associated with a poor prognosis in acute myelogenous leukemia. Furthermore, cytokine production by leukemia cells is believed to play an important role in determining the proliferative characteristics of leukemia. The in vivo effects of two noncytotoxic agents on these parameters were determined in 33 acute myelogenous leukemia patients. Three daily doses of interleukin (IL) 4 or a single dose of amifostine reduced telomerase activity in the leukemia marrow cells in 7 of 9 and 11 of 13 patients, respectively. The administration of a single dose of amifostine resulted in a reduction in tumor necrosis factor α and IL-6 transcript levels in the marrow cells of 10 of 13 and 12 of 13 patients in which these transcripts were present. The administration of only three doses of IL-4 or a single dose of amifostine has a significant effect on leukemia cell parameters, which are believed to have a significant impact on the in vivo biology of the disease and on its response to remission induction therapy.",
author = "Preisler, {H. D.} and Biaoru Li and J. Yang and Huang, {R. W.} and E. Devemy and P. Venugopal and M. Tao and H. Chopra and Gregory, {S. A.} and S. Adler and S. Sivaraman and P. Toofanfard and A. Jajeh and A. Galvez and E. Robin",
year = "2000",
month = "3",
day = "1",
language = "English (US)",
volume = "6",
pages = "807--812",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4

AU - Preisler, H. D.

AU - Li, Biaoru

AU - Yang, J.

AU - Huang, R. W.

AU - Devemy, E.

AU - Venugopal, P.

AU - Tao, M.

AU - Chopra, H.

AU - Gregory, S. A.

AU - Adler, S.

AU - Sivaraman, S.

AU - Toofanfard, P.

AU - Jajeh, A.

AU - Galvez, A.

AU - Robin, E.

PY - 2000/3/1

Y1 - 2000/3/1

N2 - High levels of telomerase activity and high rates of cell proliferation are associated with a poor prognosis in acute myelogenous leukemia. Furthermore, cytokine production by leukemia cells is believed to play an important role in determining the proliferative characteristics of leukemia. The in vivo effects of two noncytotoxic agents on these parameters were determined in 33 acute myelogenous leukemia patients. Three daily doses of interleukin (IL) 4 or a single dose of amifostine reduced telomerase activity in the leukemia marrow cells in 7 of 9 and 11 of 13 patients, respectively. The administration of a single dose of amifostine resulted in a reduction in tumor necrosis factor α and IL-6 transcript levels in the marrow cells of 10 of 13 and 12 of 13 patients in which these transcripts were present. The administration of only three doses of IL-4 or a single dose of amifostine has a significant effect on leukemia cell parameters, which are believed to have a significant impact on the in vivo biology of the disease and on its response to remission induction therapy.

AB - High levels of telomerase activity and high rates of cell proliferation are associated with a poor prognosis in acute myelogenous leukemia. Furthermore, cytokine production by leukemia cells is believed to play an important role in determining the proliferative characteristics of leukemia. The in vivo effects of two noncytotoxic agents on these parameters were determined in 33 acute myelogenous leukemia patients. Three daily doses of interleukin (IL) 4 or a single dose of amifostine reduced telomerase activity in the leukemia marrow cells in 7 of 9 and 11 of 13 patients, respectively. The administration of a single dose of amifostine resulted in a reduction in tumor necrosis factor α and IL-6 transcript levels in the marrow cells of 10 of 13 and 12 of 13 patients in which these transcripts were present. The administration of only three doses of IL-4 or a single dose of amifostine has a significant effect on leukemia cell parameters, which are believed to have a significant impact on the in vivo biology of the disease and on its response to remission induction therapy.

UR - http://www.scopus.com/inward/record.url?scp=12944332006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944332006&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 807

EP - 812

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -